Public health officials and infectious disease experts are sounding alarms about an anticipated severe flu season in the U.S. and U.K., citing early spread of the H3N2 strain, falling vaccination rates, and vaccine mismatch to current viral variants. Australia’s record-breaking 2024 flu season is seen as a warning sign for the Northern Hemisphere. Dr. Jacob Glanville of Centivax warned the U.K. is experiencing ‘cases triple compared to last year,’ while Dr. Ravi Jhaveri noted early flu activity in the U.S. and a concerning decline in vaccination rates since the pandemic. The H3N2 strain, known for its potential to cause severe illness and higher hospitalization rates, is now dominant, with vaccines containing outdated strains from 2021-2023. Experts caution that while vaccination remains critical, protection may be ‘partial at best,’ particularly for older adults and high-risk groups. The shift in respiratory virus patterns, influenced by improved RSV prevention options, may also contribute to an unpredictable flu season.
Australia’s 2024 flu season, described as the worst on record, has raised concerns about similar outcomes in the Northern Hemisphere. Dr. Glanville linked this pattern to a potential severe flu wave in the U.S. and U.K., with the H3N2 strain showing increased virulence. Researchers are still investigating why the virus is spreading earlier than usual, though Dr. Jhaveri suggested changes in respiratory virus interaction dynamics may be at play. He noted that while flu seasons historically coincided with the end of RSV circulation, the availability of RSV prevention options could have altered this pattern, leading to earlier flu activity.
Vaccination remains the primary defense against influenza, though experts acknowledge limitations. Dr. Glanville highlighted that current vaccines contain strains from 2021-2023, creating a mismatch with the evolving virus. This could reduce vaccine efficacy, particularly for vulnerable populations. Meanwhile, immunity from both vaccination and prior infections is waning over time, especially in older adults. Despite these challenges, Dr. Jhaveri emphasized that vaccines still offer ‘usual levels of protection’ based on Australian data. For those hesitant to visit clinics, new nasal spray vaccines approved for home administration provide an alternative. Centivax’s development of a universal flu vaccine, entering human trials in 2026, represents a long-term solution to combat viral mutations and seasonal drift.
High-risk groups—including individuals with chronic conditions, weakened immune systems, obesity, pregnant women, and young children—should take extra precautions. Dr. Jhaveri noted that about half of children who die from flu-related complications have no prior risk factors, underscoring the importance of vaccination. Public health messaging continues to stress the need for early immunization, particularly as the flu season approaches. While the exact severity of the coming season remains uncertain, the combination of early activity, strain-specific risks, and declining immunity has prompted officials to prepare for a potentially challenging influenza wave.